Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.

AtaiBeckley presented clinical and preclinical data at the 64th Annual ACNP Meeting in Nassau, Bahamas. The company's Phase 2b study of BPL-003 (mebufotenin benzoate) nasal spray for treatment-resistant depression showed significant rapid and sustained antidepressant effects at 8mg and 12mg doses compared to control, with good tolerability. The presentation was selected for the prestigious Hot Topics Session. Additionally, preclinical data on 5-MeO-DMT's pharmacology and potential neuroplasticity effects were presented.

AtaiBeckley Inc (NASDAQ: ATAI), formed from the merger of atai Life Sciences and Beckley Psytech, announced its 2026 outlook ahead of the J.P. Morgan Healthcare Conference. The company reported positive Phase 2b data for BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, with Phase 3 trials expected in Q2 2026. Additional milestones include Phase 2 data for VLS-01 (DMT buccal film) in H2 2026 and EMP-01 (oral R-MDMA) for social anxiety disorder in Q1 2026. The company completed its redomiciliation to the United States in December 2025 and was added to the NASDAQ Biotechnology Index.

Atai Life Sciences received FDA Breakthrough Therapy designation for BPL-003, a nasal spray targeting treatment-resistant depression. The company also raised approximately $130 million through a stock offering to advance its clinical programs.

atai Life Sciences plans to raise approximately $130 million through a public offering of 23,725,000 common shares at $5.48 per share, with proceeds intended to advance clinical development of product candidates and support corporate operations.

atai Life Sciences received a multi-year, milestone-driven grant from NIDA to develop novel non-hallucinogenic 5-HT2A/2C receptor agonists for treating opioid use disorder, focusing on innovative drug discovery approaches.

Atai Life Sciences reported Q2 2025 financial results with mixed performance, including revenue of $0.72 million, reduced net loss of $27.7 million, and continued progress in mental health treatment drug development, with a strategic combination with Beckley Psytech planned.

atai Life Sciences and Beckley Psytech reported successful Phase 2b clinical trial results for BPL-003, a potential treatment for treatment-resistant depression, demonstrating rapid and durable antidepressant effects with a single intranasal dose and minimal side effects.

Halper Sadeh LLC, an investor rights law firm, is investigating LENSAR, Atai Life Sciences, and iCAD for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.

Class action attorney Juan Monteverde is investigating the mergers of Atai Life Sciences, Blueprint Medicines, and Crown Electrokinetics to determine if the deals are fair for shareholders.

Class Action Attorney Juan Monteverde is investigating the mergers of Blueprint Medicines Corporation, Atai Life Sciences N.V., and Crown Electrokinetics Corp. to determine if the deals are fair for shareholders.

Class action attorney Juan Monteverde is investigating the mergers of Crown Electrokinetics Corp., Atai Life Sciences N.V., and Blueprint Medicines Corporation to determine if the deals are fair for shareholders.